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Background/objectives: Between 1982 and 2011, 84 clinical studies were performed by the manufacturers
of Inﬂuvac, including the annual update studies required for licensing in Europe. This paper presents
data from a 30-year evaluation of clinical experience with Inﬂuvac.
Subjects and methods: In all, 8776 subjects were vaccinated with Inﬂuvac, including healthy adults,
healthy elderly subjects, adult and elderly at-risk subjects, and healthy and at-risk children. All subjects
received the trivalent inactivated subunit inﬂuenza vaccine Inﬂuvac (Abbott, Weesp, The Netherlands).
Subjects recorded solicited local and systemic reactions for 3–7 days after vaccination. Inconvenience
was scored in some studies. Unsolicited reports of adverse events were collected up to 21 days after vac-
cination. Haemagglutination inhibition (HI) antibody titres were determined before and up to 45 weeks
after vaccination with Inﬂuvac. The immunogenicity of Inﬂuvac was assessed using the criteria of the
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Post mar-
keting surveillance data were also analyzed.
Results: Treatment-emergent adverse events up to 21 days after vaccinationwere reported by 583 of 4746
subjects (12.3%), most commonly headache. Overall, 2318 of 6825 subjects (34.0%) recorded local reac-
tions (most commonly tenderness and pain on slightest pressure) and 1229 of 6825 subjects (18.2%)
recorded systemic reactions (most commonly headache and fatigue). All local and systemic reactions were
mild or moderate and resolved in 1–2 days. Most subjects in each population group reported inconve-
nience as none-to-mild. Post marketing surveillance data collected from 1982 to 2012 indicated an overall
reporting rate of 24.5 events/million doses. The age-speciﬁc CHMP serological criteria for immunogenicity
were generally met in all the adult and elderly populations and the HI antibody titres and derived serolog-
ical parameters in children were similar to those in adults. The CHMP requirement for immunogenicity for
annual re-licensing for both healthy adults and elderly subjects was consistentlymet over the 30-year per-
iod. One study in elderly subjects demonstrated that HI antibody titres were maintained at relatively high
levels for at least 6 months, providing coverage throughout the inﬂuenza season, but by 1 year after vac-
cination antibody titres had declined to low enough levels to necessitate revaccination.
Conclusions: This review of the 30-year clinical experience with Inﬂuvac found that the overall beneﬁt-
to-risk ratio is positive for all age groups from 6 months upwards. The currently available evidence from
the many clinical trials that have been performed conﬁrms that Inﬂuvac remains an effective and safe
vaccine for preventing seasonal inﬂuenza.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Inﬂuenza is a highly infectious respiratory disease, which
causes annual epidemics that peak during winter in temperateglutination inhibition; MFI,
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-NC-ND license.regions, and occasional pandemics [1]. Although these pandemics
can be devastating (as in 1918–19) and receive much publicity,
the cumulative mortality and morbidity from seasonal inﬂuenza
during the intervening years is generally many times greater than
that associated with pandemics [2,3]. The burden of inﬂuenza is of-
ten underestimated, at least partly because the disease lacks
distinctive features, and the virus co-circulates with other respira-
tory pathogens and causes a range of nonspeciﬁc complications,
such as pneumonia and exacerbations of chronic cardiopulmonary
diseases [2]. Nevertheless, WHO estimates that worldwide,
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250,000–500,000 deaths [1]. Most of these deaths were reported in
industrialized countries among people aged 65 years or older.
The most effective method for preventing inﬂuenza infection
and its complications is inﬂuenza vaccination [4]. Inﬂuenza vac-
cines are both clinically effective and cost-effective [5,6] and may
be cost-saving among working adults (by reducing absenteeism
due to illness) and in the elderly (by reducing the need for medical
intervention) [5–7]. Annual inﬂuenza vaccination is recommended
by WHO for anyone over 6 months old with chronic medical con-
ditions, the elderly, pregnant women, healthcare workers, nursing
home residents, and other nationally deﬁned groups [8], while the
US Centers for Disease Control now recommend that everyone
aged 6 months and over should be vaccinated against inﬂuenza
[4]. Many national authorities worldwide recommend annual
inﬂuenza vaccination for the elderly and those with high-risk med-
ical conditions. However, not all of them provide public reimburse-
ment for vaccination through national or social health insurance,
though reimbursement correlates strongly with improved vaccine
coverage [9].
The inﬂuenza vaccine brand Inﬂuvac has been marketed con-
tinuously since 1950. Initially a whole-virus vaccine, Inﬂuvac
has been an inactivated surface antigen (subunit) inﬂuenza vaccine
since 1982. Since 1992, it has been a trivalent vaccine containing
15 lg haemagglutinin (HA) per strain, and since 2004 it has been
thiomersal-free. Between 1982 and 2011, 84 clinical studies were
performed by the manufacturers of Inﬂuvac, including the annual
update studies required for licensing in Europe [10]. This paper
presents data from a 30-year evaluation of clinical experience with
Inﬂuvac, extending the 15-, 20- and 25-year safety and immuno-
genicity observations [11–13] to conﬁrm the appropriateness of
this vaccine for the control of inﬂuenza.2. Subjects and methods
2.1. Overview of studies
Between 1982 and 2011, 84 clinical studies were performed
with Inﬂuvac, consisting of 32 annual update studies, 18
randomized parallel-group studies, 12 open uncontrolled studies,
10 randomized dose-comparison studies, six non-randomized
revaccination studies, four randomized lot-consistency studies,
and two randomized booster studies (Table 1). The main popula-
tions studied were healthy adults aged 18–60 years, healthy
elderly subjects aged over 60 years, and adult and elderly subjects
at risk of inﬂuenza-related complications owing to an underlying
chronic condition or to being a nursing home resident aged
18 years or over. One study enrolled healthy children aged
3–12 years [14] and one study enrolled at-risk children aged 6–
59 months with chronic lung disease or congenital heart disease
[15]. Six of the studies (enrolling 647 subjects in total) examined
the safety and immunogenicity of revaccination; four of them
enrolled healthy adults, one enrolled healthy elderly subjects and
one at-risk subjects. One study in 206 healthy elderly subjects
examined the long-term immunogenicity of Inﬂuvac.
In all, 8776 subjects were vaccinated with Inﬂuvac, of whom
1948 were excluded from the review. The reasons for exclusion
were that they did not receive a trivalent vaccine formulation
(664 subjects), they did not receive a dose of 10 or 15 lg HA per
strain (463 subjects), they received more than one dose of vaccine
(135 subjects), an experimental adjuvant was tested in the study
(153 subjects), they were included in an extension study (414 sub-
jects), their age was unknown (9 subjects), or no safety data were
available (110 subjects). A further 208 subjects were excluded
from the immunogenicity sample because they had been excludedfrom the intention-to-treat sample in the original study (184 sub-
jects) or they were known non-responders (24 subjects) before
vaccination. The safety population thus consisted of 6828 unique
subjects and the immunogenicity population of 6620 unique
subjects.
Ethical approval was granted for all studies, and written in-
formed consent was obtained for all subjects before enrolment.
All studies complied with the Good Clinical Practice guidelines of
the International Conference on Harmonization, and the Declara-
tion of Helsinki.
2.2. Inﬂuenza vaccine composition and delivery
The inﬂuenza vaccine used in these studies was Inﬂuvac (Ab-
bott, Weesp, The Netherlands), a trivalent subunit vaccine that
contained 10 lg HA per virus strain per dose (before 1992) or
15 lg HA per virus strain per dose (from 1992 onwards) according
to WHO annual strain recommendations. Before 2004 the vaccine
contained thiomersal as preservative; since 2004, Inﬂuvac has
been thiomersal-free. Since 1986, Inﬂuvac has been delivered
using the DupharJect syringe system, which has a 1-inch needle
length that ensures effective intramuscular delivery of the vaccine
[4].
2.3. Safety and immunogenicity data collection
Subjects were asked to record solicited local (at the injection
site) and systemic (general) reactions (see Table 3 for speciﬁcation)
in a daily diary for 3–7 days after vaccination. In early studies, local
and systemic reactions were scored on a binary scale as present or
not present. Inmore recent studies, reactionswere scored on a four-
point scale as none, mild, moderate, or severe. For these recent
studies, the scores were re-coded as none = not present and mild/
moderate/severe = present. In some of the studies, overall inconve-
nience after vaccination was also recorded in the daily diary. In
most of the studies in which it was assessed, overall inconvenience
after vaccination was scored on a four-point scale as none, mild/
slight, moderate, or severe. In some studies, however, inconve-
nience was scored on a three-point scale as not/hardly, moderate,
or severe. In this overview, therefore, inconvenience is presented
using a three-point scale as none-to-mild (not interfering with nor-
mal daily activities), moderate (some impact on normal daily activ-
ities), or severe (prevents normal daily activities), after re-coding
scores of none, not/hardly, mild or slight as none-to-mild. Except
in the earliest studies, unsolicited reports of adverse events were
also collected up to 21 days after vaccination and assigned a
MedDRA Preferred Term. In two studies, data on serious adverse
events and new chronic illnesses were collected up to 6 months
post-vaccination in healthy adult and elderly subjects.
For all studies, haemagglutination inhibition (HI) antibody titres
were determined [16] in blood samples drawn before and
2–4 weeks after vaccination with Inﬂuvac. In one study in elderly
subjects, blood samples were also collected at 24 weeks and about
45 weeks after vaccination with Inﬂuvac. HI titres were summa-
rized using the standard parameters seroprotection rate (propor-
tion of subjects with a titreP 40), seroconversion rate
(proportion of subjects with a pre-vaccination titre < 10 and a
post-vaccination titreP 40, or a pre-vaccination titreP 10 and a
post-vaccination relative increase ofP 4-fold), and the geometric
mean fold increase (geometric MFI; geometric mean of the intra-
individual fold increases in HI titre).
2.4. Safety and immunogenicity data analysis
Throughout the period of this review, similar inclusion criteria
were used in the studies to enrol subjects, and similar methods
Table 1
Summary of 84 studies performed with Inﬂuvac, 1982–2010. These study populations do not overlap with each other.
Type of study Number of
studies
Study population (number of vaccinated subjects)
Healthy
adults
Healthy elderly
subjects
At-risk adult and elderly
subjectsa
Healthy
children
At-risk
children
Annual update, open-label 32 1294 1167 0 0 0
Randomized, parallel-group 18 1268 1118 710 230 0
Randomized, dose-comparison 9 816 0 201 0 0
Non-randomized, dose
comparison
1 96 0 0 0 0
Randomized, lot consistency 4 442 29 0 0 0
Randomized, booster 2 60 60 0 0 0
Non-randomized, revaccination 6 350 252 45 0 0
Open, uncontrolled 12 406 160 20 0 52
Total 84 4732 2786 976 230 52
a Includes 1 study in atopic subjects.
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data from the entire 30-year period to be pooled into a single
database.
Only unsolicited adverse events (treatment-emergent adverse
events that occurred or became more severe after vaccination) that
occurred up to 21 days after vaccination in the clinical studies were
included in the pooled analysis. Data on serious adverse events and
new chronic illnesses that occurred up to 6 months post-vaccina-
tion were pooled from two studies in healthy adults and elderly.
The immunogenicity of Inﬂuvac was assessed using the crite-
ria of the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency [10]. For healthy adults
aged 18–60 years, the criteria require seroconversion in more than
40% of vaccinated subjects, and/or seroprotection in more than 70%
of vaccinated subjects, and/or a geometric MFI of 2.5 or more; in
people over 60 years old, seroconversion is required in more than
30% of vaccinated subjects, and/or seroprotection in more than
60% of vaccinated subjects, and/or a geometric MFI of at least 2.
At least one of these criteria must be fulﬁlled for each virus strain
contained in the vaccine to obtain annual marketing authorization
for established inactivated inﬂuenza vaccines in adults and the el-
derly. There are currently no accepted criteria for immunogenicity
in children, so the immunogenicity criteria for healthy adults were
applied to assess the immunogenicity of Inﬂuvac in children.2.5. Post-marketing surveillance
Since 1982, all reports of adverse reactions after vaccination
with Inﬂuvac (whether or not a relationship is established) from
health authorities, individual physicians, medical literature, and
consumers have been entered in a postmarketing surveillance
database. All reports are coded using MedDRA and evaluated to as-
sess a potential cause-effect relationship. The postmarketing sur-
veillance database does not include adverse events that occurred
during clinical studies.3. Results
3.1. Subject disposition
Overall, 50.1% of the 6828 subjects included in the safety popu-
lation were healthy adults aged 18–60 years, 36.6% were healthy
elderly subjects aged over 60 years, 9.2% were adult and elderly
at-risk, 3.4% were healthy children aged 3–12 years and 0.8% were
at-risk children. Overall, 3125 of the 6828 subjects (45.8%) be-
longed to a group with a recommendation for inﬂuenza vaccina-
tion in European Union countries (elderly over 60 years old and
at-risk subjects). In the safety population, the mean age (±SD) ofthe healthy adults was 31.4 ± 12.5 years, that of the healthy elderly
was 69.0 ± 6.6 years, and that of the adult and elderly at-risk sub-
jects was 69.4 ± 15.8 years. Among the children in the safety pop-
ulation, the mean age of the healthy children was 8.1 ± 2.6 years,
and that of the at-risk children was 19.5 ± 12.6 months. The pro-
portion of females varied between 50.0% and 58.0%.
3.2. Treatment-emergent adverse events after vaccination with
Inﬂuvac
Reports on the occurrence of unsolicited adverse events were
available for 4746 of the 6828 subjects (69.5%) in the safety popu-
lation. Treatment-emergent adverse events that occurred up to
21 days after vaccination were reported by 583 of the 4746 sub-
jects (12.3%). They were most common in at-risk children (31/52
subjects; 59.6%) and least common in healthy children (3/230 sub-
jects; 1.3%). For the other populations, treatment-emergent ad-
verse events occurred in 238/1918 (12.4%) healthy adults, in 115/
542 (21.2%) adult and elderly at-risk subjects, and in 196/2004
(9.8%) healthy elderly subjects.
The most commonly reported treatment-emergent adverse
events are shown in Table 2. At-risk children experienced a wide
range of treatment-emergent adverse events, ranging in frequency
from 3.8% to 28.8%, but only two events (two brief febrile episodes
associated with cough) were considered related to the vaccination.
In the 230 healthy children, the only treatment-emergent adverse
events reported were acute tonsillitis, dizziness and cough, each in
one child. Three deaths occurred within 21 days after vaccination,
all among elderly (aged 75 years or older) at-risk subjects. All
deaths were considered unrelated or unlikely to be related to the
vaccination.
In two studies involving 500 healthy adults and 711 healthy el-
derly subjects in total, safety data on serious adverse events and
new chronic illnesses were collected in the period 21 days to
6 months post-vaccination. In the adult population, seven new
chronic illnesses and seven serious adverse events were reported;
in the elderly population, 42 new chronic illnesses and 31 serious
adverse events were reported. None of the events was considered
related to the vaccination. In the elderly population, two deaths oc-
curred in the period 21 days to 6 months post-vaccination, which
were both considered unrelated to the vaccination.
3.3. Reactogenicity of Inﬂuvac
Data on the reactogenicity of Inﬂuvac were available for 6825
of the 6828 subjects (over 99.9%) in the safety population. Overall,
2318 subjects (34.0%) recorded local reactions and 1239 subjects
(18.2%) recorded systemic reactions. However, local reactions were
reported for only 12/230 (5.2%) healthy children and systemic
Table 2
Unsolicited treatment-emergent adverse events reported by 1% or more of adult and elderly subjects and at-risk children in the safety population after vaccination with Inﬂuvac.
In the group of 230 healthy children, only three treatment-emergent adverse events in total were reported. Blank cells indicate that <1% of subjects in that population reported the
adverse event.
Adverse event Reporting rate of treatment-emergent adverse events [% (n cases)]
Healthy adults
(n = 1918)
Healthy elderly subjects
(n = 2004)
At-risk adult and elderly subjects
(n = 542)
At-risk children
(n = 52)
Headache 2.4% (46) 1.0% (20) 1.3% (7)
Pyrexia 15.4% (8)
Vomiting 13.5% (7)
Upper respiratory tract
infection
2.0% (11)
Irritability 17.3% (9)
Cough 13.5% (7)
Crying 11.5% (6)
Diarrhoea 11.5% (6)
Rhinorrhoea 11.5% (6)
Erythema 9.6% (5)
Insomnia 9.6% (5)
Anorexia 7.7% (4)
Asthma 7.7% (4)
Poor quality sleep 7.7% (4)
Malaise 5.8% (3)
Abnormal breath sounds 3.8% (2)
Hyperhidrosis 3.8% (2)
Rhinitis 3.8% (2)
Teething 3.8% (2)
Wheezing 3.8% (2)
Nasopharyngitis 1.3% (7) 3.8% (2)
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systemic reactions reported were assessed as mild or moderate
and resolved in 1–2 days.
The most common local reaction in the healthy adult and
healthy elderly safety populations was tenderness, followed by
pain on the slightest pressure (Table 3). In adult and elderly at-risk
subjects it was pain on the slightest pressure. The most common
local reaction in the at-risk children was redness at the injection
site (11.5%); other local reactions reported were ecchymosis
(5.8%) and induration (7.7%). The only local reaction reported
among the healthy children in the safety population was continu-
ous pain in 11 children (4.8%).
The most common systemic reactions (Table 3) were fatigue
and headache in the healthy adult and healthy elderly safety pop-
ulations, and headache in the adult and elderly at-risk subjects. The
most common systemic reactions in the at-risk children were fever
(26.9%), insomnia and increased irritability (25.0% both), increased
crying and loss of appetite (15.4%), and increased sweating and
malaise (11.5%). The only systemic reaction reported among the
healthy children was headache in one child.
Inconvenience data were available for 5729 of the 6828 subjects
(83.9%) in the safety population. Inconvenience data were not col-
lected for at-risk children. Most subjects in each population group
reported inconvenience as none-to-mild (Table 4). Moderate and
severe inconvenience were reported by a very small proportion
of adult and elderly subjects.3.4. Post-marketing surveillance
Between January 1982 and January 2012, more than 380 million
doses of Inﬂuvac were distributed, and 3862 adverse event re-
ports, vaccine-related or not, were received, detailing 9313 re-
ported adverse vaccine events. This indicates a reporting rate of
24.5 events/million doses. The proﬁle of reported events has been
has been stable over the entire 30-year period.
The most commonly reported adverse events were from the
MedDRA system organ classes of general disorders and administra-
tion site conditions (2366 events, most commonly pyrexia (440
events); 6.2 events/million doses), nervous system disorders(1527 events, most commonly headache (245 events); 4.0
events/million doses), musculoskeletal and connective tissue dis-
orders (921 events, most commonly myalgia (183 events); 2.4
events/million doses), and skin and subcutaneous tissue disorders
(868 events, most commonly urticaria (136 events); 2.3 events/
million doses). In all, 103 reports of Guillain–Barré syndrome
(0.27 events/million doses) were received.
3.5. Immunogenicity of Inﬂuvac
Data on immunogenicity were available for 6620 subjects (Ta-
ble 5). Over the 30-year period of this review, Inﬂuvac always
met the CHMP requirement for immunogenicity for annual re-
licensing for both healthy adults and healthy elderly subjects, i.e.
meeting at least one of the three serological criteria per vaccine
strain. In some seasons, single criteria fell below the threshold,
especially for inﬂuenza B; however, in these seasons, one or both
of the other criteria for that strain were met. Overall, Inﬂuvac pro-
duced a consistent and adequate response; the average seroprotec-
tion rates were over 80% for adults and over 70% for the elderly,
which are well above the minimum CHMP requirement.
The antibody response to Inﬂuvac was generally lower in
healthy elderly subjects than in healthy adults aged 18–60 years,
and was lower in adult and elderly at-risk subjects than in healthy
adults or healthy elderly subjects. Overall, however, the age-spe-
ciﬁc CHMP serological criteria for immunogenicity were met in
all the adult and elderly populations.
The antibody response to Inﬂuvac was lower in at-risk chil-
dren than in healthy children, but overall the HI antibody titres
and derived serological parameters in children were similar to
those in healthy adults.
3.6. Long-term immunogenicity
Data on the long-term immunogenicity of Inﬂuvac in elderly
subjects derived from one study were available for 205 subjects
up to 6 months and for 192 subjects up to 1 year after vaccination
and are shown as geometric mean titres per strain in Fig. 1. Anti-
body titres peaked at 1 month and then gradually declined through
Table 3
Local and systemic solicited reactions to vaccination with Inﬂuvac reported by 5% or more of subjects in the safety population. For the group of 230 healthy children the only
reported local and systemic reactions were continuous pain (4.8%), pruritus (0.4%), headache (0.4%) and vomiting (0.4%).
Reporting rate of local or systemic reactions (%)
Healthy adults (n = 3418) Healthy elderly subjects (n = 2496) At-risk adult and elderly subjects (n = 629) At-risk children (n = 52)
Local reactions
Tenderness 39.3 15.5 and and
Pain on slightest pressure 35.1 9.7 17.2
Redness 8.6 5.1 8.6 11.5
Warmth 9.4 5.5 7.3
Continuous pain 8.7
Swelling 8.3 9.4
Impaired arm movement 9.5
Induration 8.5 7.7
Systemic reactions
Headache 11.9 8.2 12.5 and
Fatigue 14.1 8.7 and and
Malaise 7.0 5.4 6.4 11.5
Myalgia 8.9 8.7
Fever 26.9
Arthralgia 8.0
Increased crying and and and 15.4
Increased irritability and and and 25.0
Increased sweating 11.5
Insomnia 25.0
Loss of appetite and and and 15.4
a nd = Not recorded in this population.
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high levels, providing cover throughout the inﬂuenza season, but
by 1 year after vaccination antibody titres had fallen low enough
to necessitate revaccination.
4. Discussion
This review of the 30-year clinical experience with Inﬂuvac
conﬁrms and extends the earlier data reviews at 15, 20 and
25 years [11–13], and shows that the vaccine was consistently
well-tolerated and safe in healthy adult and elderly subjects, in
healthy children, and in at-risk subjects over 6 months of age.
The safety of Inﬂuvac in the clinical studies was conﬁrmed by
the low adverse event reporting rate in post-marketing surveil-
lance. The review also shows that over the entire 30-year reporting
period, Inﬂuvac always met the CHMP requirement for immuno-
genicity for annual re-licensing in all the adult and elderly popula-
tion groups studied. Thus, the safety and immunogenicity data
have been consistent over the entire 30-year reporting period.
Our analysis does have some limitations. First, the reactogenic-
ity items solicited varied slightly over the 30-year period covered
by this review. Secondly, the studies were conducted in different
countries, where perceptions of adverse events may be different.
This particularly applies to the study in healthy children, which
was conducted in China, where local and systemic reactions are
typically reported by 0–3.4% of vaccinees, compared with 20–30%
in studies from Europe and the USA [14]. In the other populations,
the frequency of reporting local and systemic adverse events was
as expected. Finally, the number of healthy and at-risk children
studied was small, and in the absence of deﬁned serological criteria
for immunogenicity in this age group, they were assessed using the
criteria for adults.
The review conﬁrms that in the elderly, the immunogenicity of
inactivated inﬂuenza vaccines like Inﬂuvac is generally lower
than in adults. It has recently been shown that the reduced anti-
body response to inﬂuenza vaccine in the elderly is mainly due
to reduced quantities of vaccine-speciﬁc antibodies rather than
to a lack of antibody avidity or afﬁnity [17]. In one study in the el-
derly, it was demonstrated that the increase in antibody titres
afforded by a single dose of Inﬂuvac was maintained for at least6 months, i.e. throughout the annual inﬂuenza season. This is con-
sistent with reports in the literature that HI antibody titres peak
after 2–4 weeks and then fall gradually over 6–12 months [18].
In the limited population of children reported in this review, the
immunogenicity of Inﬂuvac was comparable with that in healthy
adults. The efﬁcacy and safety of Inﬂuvac in healthy and high-risk
children has also been shown in several investigator-initiated trials
(reviewed in detail in Giezeman-Smits et al. [19]). Thus, Inﬂuvac
was safe and immunogenic in children with asthma [20] or cystic
ﬁbrosis [21]. In these studies, the incidence of local and systemic
reactions to Inﬂuvac was similar to that in adults, and they were
mild and transient. Although there is some evidence that live-
attenuated inﬂuenza vaccine may be more effective than
inactivated vaccine in children aged 6 months to 7 years [22], the
immunogenicity of Inﬂuvac in clinical studies is in accordance
with its effectiveness against inﬂuenza illness and its complications
in children. For example, in 579 otherwise healthy children aged
18–72 months with a history of physician-diagnosed respiratory
infection, Inﬂuvac vaccination reduced febrile respiratory tract
infections by 13–24%, the incidence of laboratory-conﬁrmed
inﬂuenza infection by over 50%, and episodes of acute otitis media
(a common complication in children) by 57–71%, compared with
the control group who received hepatitis B vaccination [23]. In this
study, Inﬂuvac was given with or without concomitant pneumo-
coccal conjugate vaccine. In a very large population-based study
in healthy children at kindergarten (6374 children) or school
(34,237 children), Inﬂuvac vaccination reduced the incidence of
inﬂuenza-like illness by over 60% compared with control popula-
tions [24]. In addition, the incidence of inﬂuenza-like illness and
associated morbidities was signiﬁcantly reduced in non-vaccinated
elderly people in the same communities where children were
vaccinated.
Two recent reviews have concluded that all of the currently
available inactivated inﬂuenza vaccine formulations are safe,
well-tolerated, immunogenic, and suitable for seasonal inﬂuenza
vaccination [25,26]. This view is supported by our analysis of the
comparative clinical trials in our database, which suggests that
Inﬂuvac has a similar safety and immunogenicity proﬁle to other
inactivated inﬂuenza vaccines. For example, the reactogenicity of
Inﬂuvac was comparable with that of Agrippal (Novartis
Table 4
Inconvenience after vaccination with Inﬂuvac in the safety population. For the group at-risk children inconvenience was not recorded.
Degree of inconvenience Proportion of subjects reporting inconvenience (%)
Healthy adults (n = 2844) Healthy elderly subjects (n = 2250) At-risk adult and elderly subjects (n = 405) Healthy children (n = 230)
None-to-mild 98.2 98.7 96.5 100
Moderate 1.5 1.2 3.2 0
Severe 0.3 0.1 0.2 0
Table 5
Immunogenicity of Inﬂuvac in the immunogenicity population.
Population Seroprotection rate (% of subjects) Seroconversion rate (% of subjects) Geometric MFI
A(H1N1) A(H3N2) B A(H1N1) A(H3N2) B A(H1N1) A(H3N2) B
Healthy adultsa (n = 3327) 85.1–98.1 89.5–98.3 78.1–97.1 64.2–89.5 64.6–83.3 51.9–83.3 9.0–32.2 8.8–19.4 5.8–17.8
Healthy elderly subjectsa (n = 2467) 71.4–88.3 74.2–95.4 59.7–89.5 40.4–71.7 49.0–71.7 37.4–68.4 3.9–11.2 5.6–12.8 3.9–10.4
At-risk adult and elderly subjectsa (n = 594) 50.0–85.7 80.0–89.4 80.3–92.4 30.0–41.8 48.5–55.0 35.0–62.7 3.2–5.6 4.9–6.4 5.2–7.9
Healthy childrenb (n = 181) 99.4 98.3 94.5 86.7 87.3 91.7 17.3 19.8 23.1
At-risk childrenb (n = 51) 70.6 54.9 70.6 70.6 54.9 68.6 10.8 5.8 10.5
a Interquartile range.
b Percentage or geometric mean observed in single study.
0
50
100
150
200
250
300
Months after vaccination
G
eo
m
et
ric
 m
ea
n 
tit
er
s
0
5
10
15
20
25
30
35
40
Months after vaccination
G
eo
m
et
ric
 m
ea
n 
tit
er
s
0
10
20
30
40
50
60
70
80
90
0 1 6 12 0 1 6 120 1 6 12
Months after vaccination
G
eo
m
et
ric
 m
ea
n 
tit
re
s
H3N2H1N1 B
Fig. 1. Long-term immunogenicity data derived from a single study of 205 elderly subjects after vaccination with Inﬂuvac: geometric mean antibody titres at 3 weeks after
vaccination, at end of season (5–6 months), and just before the next annual vaccination (11–12 months).
S.V. van de Witte et al. / Trials in Vaccinology 1 (2012) 42–48 47Vaccines), a similar inactivated subunit inﬂuenza vaccine [14]. An
investigator-led study has shown that Inﬂuvac is less locally reac-
togenic in adults than the split-virion vaccine Fluvax (CSL Biother-
apies), though there was no difference in systemic reactogenicity
[27]. However, the reactogenicity of Inﬂuvac is signiﬁcantly lower
than that of adjuvanted inﬂuenza vaccines, such asMF59-adjuvant-
ed Fluad (Novartis Vaccines). For example, one randomized com-
parative trial contained in the database found that local and
systemic reactionswere experienced by 46% and 32% of elderly sub-
jects receiving Fluad, but by only 19% and 22% of subjects receiving
Inﬂuvac [28]. Although the antibody response is slightly but sig-
niﬁcantly higher after vaccination with adjuvanted vaccine than
after vaccination with non-adjuvanted vaccine, this may have only
a very modest impact on clinical protection [25] and comes at the
cost of greater reactogenicity. Overall, the proﬁle of adverse events
reported for inﬂuenza vaccinesmatches the class summary of prod-
uct characteristics, which are similar for Inﬂuvac and other inacti-
vated inﬂuenza vaccines.5. Conclusions
This review of the 30-year clinical experience with Inﬂuvac
found that the overall beneﬁt-to-risk ratio is positive for all age
groups from 6 months upwards. The currently available evidence
from the many clinical trials that have been performed conﬁrmsthat Inﬂuvac remains an effective and safe vaccine for preventing
seasonal inﬂuenza. Increased antibody titres were maintained
throughout the inﬂuenza season, but by 1 year after vaccination
antibody titres had declined to low enough levels to necessitate
revaccination for the following inﬂuenza season. The safety of this
marketed product is continuously monitored through ongoing
pharmacovigilance, which shows that the safety proﬁle is as ex-
pected from the summary of product characteristics.Acknowledgement
Dr. Georgina Hutber provided writing assistance which was
funded by Abbott.References
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